Zobrazeno 1 - 10
of 71
pro vyhledávání: '"Jozien, Helleman"'
Autor:
Sebastiaan Remmers, Jozien Helleman, Daan Nieboer, Bruce Trock, Matthew E. Hyndman, Caroline M. Moore, Vincent Gnanapragasam, Lui Shiong Lee, Oussama Elhage, Laurence Klotz, Peter Carroll, Tom Pickles, Anders Bjartell, Grégoire Robert, Mark Frydenberg, Mikio Sugimoto, Behfar Ehdaie, Todd M. Morgan, Jose Rubio-Briones, Axel Semjonow, Chris H. Bangma, Monique J. Roobol
Publikováno v:
European Urology Open Science, Vol 41, Iss , Pp 126-133 (2022)
Background: Active surveillance (AS) is a management option for men diagnosed with low-risk prostate cancer. Opinions differ on whether it is safe to include young men (≤60 yr) or men with intermediate-risk disease. Objective: To assess whether rea
Externí odkaz:
https://doaj.org/article/a460e28542014822b7a8ac0483ebc3c7
Autor:
Kerri Beckmann, Aida Santaolalla, Jozien Helleman, Peter Carroll, Byung Ha Chung, Lui Shiong Lee, Antoinette Perry, Jose Rubio-Briones, Mikio Sugimoto, Bruce Trock, Riccardo Valdagni, Prokar Dasgupta, Mieke Van Hemelrijck, Oussama Elhage
Publikováno v:
European Urology Open Science, Vol 34, Iss , Pp 47-54 (2021)
Background: Studies of active surveillance (AS) for prostate cancer (PCa) have focussed predominantly on Caucasian populations. Little is known about the experience of Asian men, while suitability for men of African descent has been questioned. Objec
Externí odkaz:
https://doaj.org/article/2e6651f999d846eda60cb62fe5759d77
Autor:
Kerri R, Beckmann, Chris H, Bangma, Jozien, Helleman, Anders, Bjartell, Peter R, Carroll, Todd, Morgan, Daan, Nieboer, Aida, Santaolalla, Bruce J, Trock, Riccardo, Valdagni, Monique J, Roobol
Publikováno v:
Prostate, 82(7), 876-879. Wiley-Liss Inc.
2022, ' Comparison of outcomes of different biopsy schedules among men on active surveillance for prostate cancer : An analysis of the G.A.P.3 global consortium database ', Prostate, vol. 82, no. 7, pp. 876-879 . https://doi.org/10.1002/pros.24330
2022, ' Comparison of outcomes of different biopsy schedules among men on active surveillance for prostate cancer : An analysis of the G.A.P.3 global consortium database ', Prostate, vol. 82, no. 7, pp. 876-879 . https://doi.org/10.1002/pros.24330
Refereed/Peer-reviewed Background: The optimal interval for repeat biopsy during active surveillance (AS) for prostate cancer is yet to be defined. This study examined whether risk of upgrading (to grade group ≥ 2) or risk of converting to treatmen
Autor:
Paul Doan, Lin Zhu, Sebastiaan Remmers, Daan Nieboer, Jozien Helleman, Peter Carroll, Kyochul Koo, Andrew Hayen, James Thompson, Chris Bangma
Publikováno v:
Journal of Urology. 209
Autor:
Reuben S. Harris, Scott H. Kaufmann, Kimberly R. Kalli, William L. Brown, Brett D. Anderson, John W.M. Martens, Els M.J.J. Berns, Anieta M. Sieuwerts, Jozien Helleman, Olivier De Wever, Jo Van Dorpe, Mieke Van Bockstal, Ann L. Oberg, Matthew J. Maurer, Gabriel J. Starrett, Brandon Leonard
Purpose: APOBEC3 DNA cytosine deaminase family members normally defend against viruses and transposons. However, deregulated APOBEC3 activity causes mutations in cancer. Because of broad expression profiles and varying mixtures of normal and cancer c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8362452eadd51419a694087c9ef3e0e8
https://doi.org/10.1158/1078-0432.c.6525488.v1
https://doi.org/10.1158/1078-0432.c.6525488.v1
Autor:
Els M.J.J. Berns, John A. Foekens, Stefan Sleijfer, Jan G.M. Klijn, Anieta M. Sieuwerts, Marion E. Meijer-van Gelder, Maxime P. Look, Iris L. van Staveren, Kirsten Ruigrok-Ritstier, Maurice P.H.M. Jansen, Jozien Helleman
Supplementary Tables S1-S3 from Association of an Extracellular Matrix Gene Cluster with Breast Cancer Prognosis and Endocrine Therapy Response
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::32957e3a84a8528b37396cd7876730d9
https://doi.org/10.1158/1078-0432.22439650.v1
https://doi.org/10.1158/1078-0432.22439650.v1
Autor:
Reuben S. Harris, Scott H. Kaufmann, Kimberly R. Kalli, William L. Brown, Brett D. Anderson, John W.M. Martens, Els M.J.J. Berns, Anieta M. Sieuwerts, Jozien Helleman, Olivier De Wever, Jo Van Dorpe, Mieke Van Bockstal, Ann L. Oberg, Matthew J. Maurer, Gabriel J. Starrett, Brandon Leonard
Table S1 has RTqPCR primers and probe information. Table S2 has clinical information for the Dutch cohort. Table S3 has a summary of TCGA samples used in our analyses. Figure S1 has RTqPCR assay validation data. Figure S2 shows clinical correlations
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::41fd030e861870d9b288a8be767ff126
https://doi.org/10.1158/1078-0432.22463711.v1
https://doi.org/10.1158/1078-0432.22463711.v1
Autor:
Jonathan Olivier, Weiyu Li, Daan Nieboer, Jozien Helleman, Monique Roobol, Vincent Gnanapragasam, Mark Frydenberg, Mikio Sugimoto, Peter Carroll, Todd M. Morgan, Riccardo Valdagni, Jose Rubio-Briones, Grégoire Robert, Phillip Stricker, Andrew Hayen, Ivo Schoots, Masoom Haider, Caroline M. Moore, Brian Denton, Arnauld Villers, Bruce Trock, Behfar Ehdaie, Christopher Filson, Christopher Logothetis, Todd Morgan, Laurence Klotz, Tom Pickles, Eric Hyndman, Caroline M Moore, Mieke Van Hemelrijck, Prokar Dasgupta, Chris Bangma, Axel Semjonow, Antti Rannikko, Antoinette Perry, Jonas Hugosson, Anders Bjartell, Lukas Hefermehl, Lee Lui Shiong, Byung Ha Chung, Theo van der Kwast, Tim Hulsen, Wim van der Linden, Boris Ruwe, Peter van Hooft, Ewout Steyerberg, Paul Boutros, Wei Guo, Nicole Benfante, Janet Cowan, Dattatraya Patil, Lauren Park, Stephanie Ferrante, Alexandre Mamedov, Vincent LaPointe, Trafford Crump, Vasilis Stavrinides, Jenna Kimberly-Duffell, Aida Santaolalla, Tiziana Rancati, Helén Ahlgren, Juanma Mascarós, Annica Löfgren, Kurt Lehmann, Catherine Han Lin, Thomas Cusick, Hiromi Hirama, Kwang Suk Lee, Guido Jenster, Anssi Auvinen, Kees van Bochove, Michelle Kouspou, Kellie Paich
Publikováno v:
European Urology Open Science
European Urology Open Science, 35, 59-67. Elsevier
European Urology Open Science, 35, 59-67. Elsevier
Take Home Messages Among men with low- or intermediate-risk prostate cancer who choose active surveillance, those with suspicious magnetic resonance imaging (MRI) at the time of inclusion in active surveillance are more likely to show switch to treat
Autor:
Silvia R. Vitale, Floris H. Groenendijk, Ronald van Marion, Corine M. Beaufort, Jean C. Helmijr, Hendrikus Jan Dubbink, Winand N. M. Dinjens, Patricia C. Ewing-Graham, Ramon Smolders, Helena C. van Doorn, Ingrid A. Boere, Els M. J. J. Berns, Jozien Helleman, Maurice P. H. M. Jansen
Publikováno v:
Biomolecules, Vol 10, Iss 3, p 415 (2020)
The aim of this study was to determine an optimal workflow to detect TP53 mutations in baseline and longitudinal serum cell free DNA (cfDNA) from high-grade serous ovarian carcinomas (HGSOC) patients and to define whether TP53 mutations are suitable
Externí odkaz:
https://doaj.org/article/76c9e3e5ee1348d4b952b7c5f009f099
Autor:
R Trafford, Crump, Sebastiaan, Remmers, Mieke, Van Hemelrijck, Jozien, Helleman, Daan, Nieboer, Monique J, Roobol, Lionne D F, Venderbos
Publikováno v:
Transl Androl Urol
Translational Andrology and Urology, 10(6), 2719-2727. AME Publishing Company
Translational Andrology and Urology, 10(6), 2719-2727. AME Publishing Company
Background: Active surveillance (AS) for low-risk prostate cancer (PCa) is intended to overcome potential side-effects of definitive treatment. Frequent prostate biopsies during AS may, however, impact erectile (EF) and urinary function (UF). The obj